ArticleInflammation2026
Red Blood Cell-Derived Exosomes Deliver Complement C5 to Exacerbate Neuroinflammation and Neuronal Injury after Intracerebral Hemorrhage.
Article in Inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intracerebral hemorrhage (ICH) induces neuroinflammation and neuronal damage, partially driven by microglial necroptosis and M1 polarization. Recent evidence implicates red blood cell-derived exosomes (RBC-Exos) in inflammatory pathologies, yet their role in ICH remains unexplored. This study investigates how hemorrhagic RBC-Exos (ICH-Exos) regulate microglial dysfunction and neuropathology through complement signaling. RBC-Exos were isolated and validated using flow cytometry (AnnexinV+CD235+), transmission electron microscopy, nanoparticle tracking analysis, and western blot (CD63/TSG101). In vitro, hemin-treated microglia were exposed to Normal-Exos or ICH-Exos. Murine ICH models assessed neuropathology via histology (H&E, Nissl staining), adhesion molecule expression (ICAM-1/VCAM-1), and neurobehavioral tests. Proteomics identified exosomal protein cargo, complemented by C5 monoclonal antibody (mAb) blocking experiments to dissect mechanistic pathways. ICH-Exos exacerbated hemin-induced microglial necroptosis, marked by upregulated phosphorylated RIPK1, RIPK3, and MLKL, and amplified M1 polarization (elevated CD86, iNOS, CCL2; suppressed CD163, ARG1). In ICH mice, ICH-Exos aggravated cerebral hemorrhage, neuronal loss, and neurobehavioral deficits while elevating pro-inflammatory cytokines (IL-1β, IL-6, TNF-α). Proteomics revealed C5 enrichment in ICH-Exos, correlating with elevated C5a levels in serum and brain tissues. C5 mAb neutralized ICH-Exos effects, rescuing microglial viability, restoring M1/M2 equilibrium, and attenuating necroptosis. In vivo, C5 inhibition reduced hemorrhage volume, restored neuronal Nissl bodies, suppressed ICAM-1/VCAM-1, and mitigated MAPK pathway activation (p-ERK1/2, p-p38). In conclusion, ICH-Exos drive neuroinflammation and neuronal injury post-ICH by promoting C5-dependent microglial necroptosis and M1 polarization. Targeting the C5/C5a axis counteracts these effects, suggesting a novel therapeutic strategy to ameliorate ICH-related neuropathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.